{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:08:46Z","timestamp":1791446926065,"version":"4.3.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2566,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure patients, and relationships between serum potassium and adverse clinical outcomes in this population, is not well characterized. The aim of this study was to investigate associations between mortality, major adverse cardiac events, and renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi) discontinuation across serum potassium levels, in a UK cohort of incident heart failure patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a retrospective observational cohort study of newly diagnosed heart failure patients listed in the Clinical Practice Research Datalink, with a first record of heart failure (index date) between 2006 and 2015. Hypokalaemia and hyperkalaemia episodes were defined as the number of serum potassium measurements exceeding each threshold (&amp;lt;3.5, \u22655.0, \u22655.5, and \u22656.0 mmol\/L), without such a measurement in the preceding 7 days. Risk equations developed using Poisson generalized estimating equations were utilized to estimate adjusted incident rate ratios (IRRs) relating serum potassium and clinical outcomes (death, major adverse cardiac event, and RAASi discontinuation). Among 21,334 eligible heart failure patients, 1969 (9.2%), 7648 (35.9%), 2725 (12.8%), and 763 (3.6%) experienced episodes of serum potassium &amp;lt;3.5, \u22655.0, \u22655.5, and \u22656.0 mmol\/L, respectively. The adjusted IRRs for mortality exhibited a U-shaped association pattern with serum potassium. Relative to the reference category (4.5 to &amp;lt;5.0 mmol\/L), adjusted IRRs for mortality were estimated as 1.98 (95% confidence interval: 1.69\u20132.33), 1.23 (1.12\u20131.36), 1.35 (1.14\u20131.60), and 3.02 (2.28\u20134.02), for patients with serum potassium &amp;lt;3.5, \u22655.0 to &amp;lt;5.5, \u22655.5 to &amp;lt;6.0, and \u22656.0 mmol\/L, respectively. The adjusted IRRs for major adverse cardiac events demonstrated a non-statistically significant relationship with serum potassium. Discontinuation of RAASi therapy exhibited a J-shaped trend in association with serum potassium. Compared with the reference category (4.5 to &amp;lt;5.0 mmol\/L), adjusted IRRs were estimated as 1.07 (0.89\u20131.28) in patients with serum potassium &amp;lt;3.5 mmol\/L, increasing to 1.32 (1.14\u20131.53) and 2.19 (1.63\u20132.95) among those with serum potassium \u22655.5 to &amp;lt;6.0 and \u22656.0 mmol\/L, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In UK patients with new onset heart failure, both hypokalaemia and hyperkalaemia were associated with increased mortality risk, and hyperkalaemia was associated with increased likelihood of RAASi discontinuation. Our results demonstrate the potential importance of serum potassium monitoring for heart failure outcomes and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12402","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T11:02:36Z","timestamp":1547118156000},"page":"280-290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Serum Potassium and Clinical Outcomes in Heart Failure Patients: Results of Risk Calculations in 21 334 Patients in the UK"],"prefix":"10.1093","volume":"6","author":[{"given":"Cecilia","family":"Linde","sequence":"first","affiliation":[{"name":"Heart and Vascular Theme, Karolinska University Hospital and Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Global Health Economics, AstraZeneca , Gaithersburg, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Bakhai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Furuland","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Uppsala University Hospital , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[{"name":"Diabetes Resource Centre, Llandough Hospital , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ayoubkhani","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Palaka","sequence":"additional","affiliation":[{"name":"Global Health Economics, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Bennett","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]},{"name":"School of Human and Health Sciences, Swansea University , Swansea ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"2026012115100489400_ehf212402-bib-0001","first-page":"487","article-title":"Potassium disorders: hypokalemia and hyperkalemia","volume":"92","author":"Viera","year":"2015","journal-title":"Am Fam Physician"},{"key":"2026012115100489400_ehf212402-bib-0002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026012115100489400_ehf212402-bib-0003","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"2026012115100489400_ehf212402-bib-0004","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115100489400_ehf212402-bib-0005","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115100489400_ehf212402-bib-0006","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"2026012115100489400_ehf212402-bib-0007","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012115100489400_ehf212402-bib-0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena","volume":"6","author":"Epstein","year":"2016","journal-title":"Kidney International Supplements"},{"key":"2026012115100489400_ehf212402-bib-0009","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115100489400_ehf212402-bib-0010","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115100489400_ehf212402-bib-0011","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026012115100489400_ehf212402-bib-0012","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012115100489400_ehf212402-bib-0013","first-page":"c8","article-title":"Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race","volume":"120","author":"Hayes","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026012115100489400_ehf212402-bib-0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012115100489400_ehf212402-bib-0015","volume-title":"Clinical Practice Research Datalink","author":"Medicines and Healthcare Products Regulatory Agency","year":"2017"},{"key":"2026012115100489400_ehf212402-bib-0016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2026012115100489400_ehf212402-bib-0017","volume-title":"Hospital episode statistics","author":"NHS Digital"},{"key":"2026012115100489400_ehf212402-bib-0018","volume-title":"R: a language and environment for statistical computing","author":"R Core Team"},{"key":"2026012115100489400_ehf212402-bib-0019","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"2026012115100489400_ehf212402-bib-0020","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","article-title":"Serum potassium levels and outcome in patients with chronic heart failure","volume":"118","author":"Hoss","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026012115100489400_ehf212402-bib-0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00392-017-1173-3","article-title":"Association between hypo-and hyperkalemia and outcome in acute heart failure patients: the role of medications","volume":"107","author":"Legrand","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2026012115100489400_ehf212402-bib-0022","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012115100489400_ehf212402-bib-0023","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026012115100489400_ehf212402-bib-0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012115100489400_ehf212402-bib-0025","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115100489400_ehf212402-bib-0026","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"2026012115100489400_ehf212402-bib-0027","volume-title":"Summary guidelines: heart failure update","author":"Queen Mary University of London Clinical Effectiveness Group","year":"2015"},{"key":"2026012115100489400_ehf212402-bib-0028","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012115100489400_ehf212402-bib-0029","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115100489400_ehf212402-bib-0030","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115100489400_ehf212402-bib-0031","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115100489400_ehf212402-bib-0032","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115100489400_ehf212402-bib-0033","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/2\/280\/66136023\/eschf_6_2_280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/2\/280\/66136023\/eschf_6_2_280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:13:10Z","timestamp":1769026390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/2\/280\/8403615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,10]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12402","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"2018-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}